Introduction of the OMNI Edge Surgical System
Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eye care technology company, is set to unveil the latest OMNI Edge Surgical System. This new addition to their product portfolio is anticipated to make waves in the field of glaucoma treatment. Patients and healthcare professionals alike can expect significant advancements in the management of primary open-angle glaucoma through the integration of cutting-edge technology.
Features of OMNI Edge
The OMNI Edge introduces state-of-the-art features that promise to enhance surgical outcomes. Utilizing TruSync technology, the device allows for a synchronized viscoelastic delivery during the surgical procedure. This advancement enables surgeons to maintain control while treating intricate areas of the eye that are critical during glaucoma surgery.
Expanded Viscoelastic Capacity
One of the standout features is the system's ability to deliver up to 21 µL of viscoelastic material, nearly doubling the capacity of its predecessor, the OMNI Surgical System. This allows for precise targeting of the eye's major resistance points, ensuring effective drainage of intraocular fluid.
Ergonomic Design
In addition, the design retains the trusted ergonomics familiar to surgeons. Its intuitive handling enables seamless integration into existing surgical practices, minimizing the learning curve for professionals. The device is adaptable for various stages of glaucoma, either as a standalone solution or alongside cataract procedures.
Advancements in Glaucoma Care
Glaucoma is a leading cause of irreversible blindness globally, making effective treatment options vital. Sight Sciences remains committed to advancing glaucoma care through technologies that align with modern surgical practices. According to Paul Badawi, Co-Founder and CEO of Sight Sciences, the OMNI Edge is a testament to their dedication to innovation, aiming to enhance the standard of care for patients suffering from glaucoma.
Research studies have highlighted the effectiveness and durability of the OMNI procedure, showcasing its safety during both standalone and combination procedures. With over 300,000 successful applications of the technology, it has established a significant footprint in the canal-based minimally invasive glaucoma surgery (MIGS) landscape.
Event Participation and Demonstration
To gain firsthand experience of the OMNI Edge technology, attendees at the upcoming ASCRS Annual Meeting are encouraged to visit Sight Sciences' booth #2439. The event will take place in Los Angeles, where the company will showcase its latest innovations on April 26. This will also be an excellent opportunity for networking with leading physicians and industry experts in the eye care field.
About the OMNI Edge Surgical System
The OMNI Edge Surgical System is characterized by its handheld design, intended specifically for minimally invasive surgical applications. Surgeons can utilize the device to perform a canaloplasty followed by trabeculotomy, targeting the primary areas of the eye's fluid outflow pathway. This targeted approach is designed to effectively manage intraocular pressure in adults diagnosed with primary open-angle glaucoma.
As the technology continues to evolve, surgical professionals can expect ongoing updates and improvements that cater to the needs of their patients. Sight Sciences has reaffirmed its position as a leader in the industry, protected by a robust global patent portfolio that encompasses numerous patents worldwide.
About Sight Sciences
Sight Sciences is dedicated to transforming eye care via innovative, minimally invasive solutions. Their goal is to improve the standard of care for eye diseases while empowering surgeons with the tools they need to facilitate better patient outcomes. From the OMNI Surgical System to the TearCare System targeting meibomian gland dysfunction, Sight Sciences is committed to revolutionizing treatment paradigms within ophthalmology.
Frequently Asked Questions
What is the OMNI Edge Surgical System?
The OMNI Edge Surgical System is an innovative device designed for minimally invasive glaucoma surgery, featuring advanced viscoelastic delivery technology.
When will the OMNI Edge be showcased?
The OMNI Edge will debut at the ASCRS Annual Meeting, taking place on April 26, 2025, in Los Angeles.
How does the OMNI Edge improve surgical outcomes?
It enhances surgical outcomes by providing increased viscoelastic capacity and synchronized technology for better precision during procedures.
Who is the target audience for OMNI Edge?
The target audience includes eye surgeons specializing in glaucoma treatments and their patients who require effective management for primary open-angle glaucoma.
What is Sight Sciences' mission?
Sight Sciences aims to transform eye care by developing innovative and minimally invasive technologies that improve patient lives through advanced treatment options.
